Advanced oxidation protein products induce inflammatory responses and invasive behaviour in fibroblast-like synoviocytes via the RAGE-NF-κB pathway
Authors:
Open Access
- 1 April 2021
- journal article
- research article
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 10 (4) , 259-268
Abstract
Aims: Rheumatoid arthritis (RA), which mainly results from fibroblast-like synoviocyte (FLS) dysfunction, is related to oxidative stress. Advanced oxidation protein products (AOPPs), which are proinflammatory mediators and a novel biomarker of oxidative stress, have been observed to accumulate significantly in the serum of RA patients. Here, we present the first investigation of the effects of AOPPs on RA-FLSs and the signalling pathway involved in AOPP-induced inflammatory responses and invasive behaviour.Methods: We used different concentrations of AOPPs (50 to 200 µg/ml) to treat RA-FLSs. Cell migration and invasion and the expression levels of tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase-3 (MMP-3), and MMP-13 were investigated. Western blot and immunofluorescence were used to analyze nuclear factor-κB (NF-κB) activation.Results: AOPPs promoted RA-FLS migration and invasion in vitro and significantly induced the messenger RNA (mRNA) and protein expression of TNF-α, IL-6, MMP-3, and MMP-13 in dose- and time-dependent manners. Moreover, AOPPs markedly activated the phosphorylation of nuclear factor-κB (NF-κB) p65 protein, which triggered inhibitory kappa B-alpha (IκBα) degradation, NF-κB p65 protein phosphorylation, and NF-κB p65 translocation into the nucleus. Furthermore, treatment with a neutralizing antibody specific to receptor for advanced glycation end products (RAGE) significantly suppressed aggressive behaviour and inflammation, decreased TNF-α, IL-6, MMP-3, and MMP-13 expression, and blocked AOPP-induced NF-κB pathway activation.Conclusion: The results indicate that AOPPs can enhance aggressive behaviour and the inflammatory response in RA-FLSs via the RAGE–NF-κB pathway. These results present AOPPs as a new class of potentially important mediators of progressive disease in RA patients. Cite this article: Bone Joint Res 2021;10(4):259–268.Keywords
This publication has 54 references indexed in Scilit:
- Advanced Oxidation Protein Products Induce Inflammatory Response and Insulin Resistance in Cultured Adipocytes via Induction of Endoplasmic Reticulum StressCellular Physiology and Biochemistry, 2010
- Inhibition of NF‐κB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritisArthritis & Rheumatism, 2009
- Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritisImmunological Reviews, 2009
- Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanismsKidney International, 2009
- Advanced Oxidation Protein Products Activate Vascular Endothelial Cells via a RAGE-Mediated Signaling PathwayAntioxidants & Redox Signaling, 2008
- The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2008
- Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– miceJournal of Clinical Investigation, 2008
- Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritisCell Biochemistry and Function, 2005
- AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patientsKidney International, 2003
- Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2001